Authors
Latest:
Multiple Factors at Play in the Rise of Early-Onset Colorectal CancerOncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Latest:
Older Patients With Triple-Negative Breast Cancer Should Be Assessed Different for TreatmentEnrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.
Latest:
In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
Latest:
Promising Results Seen With Pembrolizumab Plus Chemoradiation in Stage III NSCLCAntitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.
Latest:
Combined Risk Factors Lead to Worse Outcomes in Colon CancerLuv N. Hajirawala, MD, discusses the findings from a retrospective analysis of the Surveillance, Epidemiology and End Results database looking at patients with stage III colon cancer.
Latest:
Unmet Needs in Oligometastatic Prostate CancerChad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.
Latest:
Using Capecitabine/Temozolomide or 177Lu-Dotatate to Treat NETs Requires Real-World GuideA real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.
Latest:
Second-Line Regorafenib/Nivolumab Is Deemed Safe for HCCFor patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.
Latest:
Evaluating PD-L1 Therapy in SCLCAriel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.
Latest:
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaMahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Latest:
Exploring Adjuvant Endocrine Therapy in the Breast Cancer SettingTerry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.
Latest:
Behind the Development of Ivaltinostat in Metastatic PDACMohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.
Latest:
Future Directions for CAR T-Cell Therapies in Solid TumorsMichael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.
Latest:
Immune Checkpoint Inhibitors Offer New Approaches in Head and Neck CancerJoseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.
Latest:
Germline Testing Outside the Guidelines: Can it Address Health Disparities?The completion of the Human Genome project has ushered in a new era in our understanding of cancer.
Latest:
Cervical Cancer Awareness Month: Trials Assess New ImmunotherapiesMargarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Latest:
Factors Correlating With Survival in Polycythemia VeraCarole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.
Latest:
Jacob Discusses Bladder Preservation as Top Refusal Reason in SunRISe-1Joseph M. Jacob, MD, discusses the key takeaways from the SunRISe-1 study and data presented at the 2024 Genitourinary Cancers Symposium.
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
Miller Discusses Novel Targets in Endometrial CancerEirwen M. Miller, MD, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.
Latest:
Next Steps in Study of PPAR-α Inhibitor Plus Nivolumab in RCCBruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.
Latest:
Social Determinants of Health Impacting Oncology TodayIn season 4, episode 11 of Targeted Talks, Krisda Chaiyachati, MD, MPH, MSHP, discusses the social determinants of health for patients with cancer and key challenges for patients, like transportation insecurity.
Latest:
Recently Introduced Low-Intensity Options for Older Patients With AMLTapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.
Latest:
Analyzing Outcomes of Immune Checkpoint Blockade Plus Chemo in SCLCAshish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.
Latest:
The New Algorithm for Second-Line Large B-Cell Lymphoma TreatmentThe diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.
Latest:
Upfront Nivolumab/Chemo Produces Durable Responses in Urothelial CarcinomaMichiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.
Latest:
Addressing the Mechanism of Action for the AKT Pathway in TNBCRebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Latest:
Advice and Future Directions for the Treatment of GISTEdwin Choy, MD, provides key recommendations for community oncologists treating patients with gastrointestinal stromal tumor.
